Search Results

DIA’s 2026 Real-World Evidence Conference will convene global regulators, industry leaders, data scientists, and policy experts to examine the latest developments shaping the field. The program will feature regulatory perspectives from agencies including the FDA, EMA, and other global authorities, alongside discussions on data quality, governance, and evolving standards for the use of real-world data in regulatory and clinical decision-making.

Structure-free AI platform delivers picomolar leads while cutting wet-lab validation to 20-50 samples per round

The FDA has granted a three-month extension for Capricor Therapeutics’ Duchenne muscular dystrophy hopeful deramiocel in order to review additional data and consider a refined indication. The new target action date for the therapy is November 22.